D. Yu. Grebenkin
Research Subjects
D. Yu. Grebenkin has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Alexei E. Miroshnikov
LLC ClinPharmInvest
4 shared publications - O. V. Lebedeva
Representative office of Sanofi-aventis group JSC (France)
4 shared publications - A. A. Khokhlov
LLC «AX CT
3 shared publications - Vasily I. Kazey
Exacte Labs
3 shared publications - A. V. Ryabova
Exacte Labs LLC
2 shared publications - E. K. Faeva
LLC "Exacte Labs, Russia
2 shared publications
Latest Publications
- 20 December 2025
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 27 (6) , 1423-1434
Development and validation of an ELISA-based method for determining neutralizing antibodies to pembrolizumab in human serum based on inhibition of the drug binding to its PD-1 target
Monoclonal antibodies (mAbs) are potentially able to trigger undesired humoral immune responses in the patients and develop ADA (anti-drug antibody) to the protein drugs. Neutralizing anti-drug antibodies are among the main factors affecting safety and effectiveness of the therapy. If it is impossible to apply cell-based tests to determine neutralizing antibodies, competitive ligand binding assay may be used as an alternative. Pembrolizumab (Pembro) is a broad-spectrum antitumor drug, being a humanized IgG4 kappa antibody to the programmed cell death receptor-1 (PD-1) that blocks interaction of this receptor with its ligands PD-L1 and PD-L2. Due to some technical issues, cell culture test is not feasible for Pembro, due to high risk of obtaining unreliable results. The aim of our study was to develop and validate a method for detection of neutralizing antibodies to Pembro in human serum based on inhibition of pembrolizumab binding to its PD-1 target. The experimental drug pembrolizumab RPH-075 (R-Pharm) was used in the study. Anti-Pembrolizumab antibodies KRIBIOLISATM Anti-Pembrolizumab (KEYTRUDA®) ELISA, India) were used as a positive control sample for neutralizing antibodies. Determination of antibodies was carried out by ELISA technique using acid dissociation of the immune complex and the Affinity capture elution (ACE) technique. The ELISA method was validated by the following characteristics: selectivity, sensitivity, specificity, “hook” effect, drug tolerance, precision. Due to the use of sample pretreatment approaches (ACE technique) for analysis of neutralizing antibodies, a sensitivity level of 100 ng/mL was achieved in the presence of pembrolizumab at 40 μg/mL. In this paper, a method was substantiated by calculating the cutoff point, sensitivity, and selectivity based on ROC analysis and floating exclusion limit (PSCP) through the average values of optical density NC and LPC in each individual analytical cycle. The developed method for determining neutralizing antibodies to pembrolizumab may be used to assess the undesirable immunogenicity of pembrolizumab at the stage of clinical trials.
- 20 December 2025
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 27 (6) , 1423-1434
Development and validation of an ELISA-based method for determining neutralizing antibodies to pembrolizumab in human serum based on inhibition of the drug binding to its PD-1 target
Monoclonal antibodies (mAbs) are potentially able to trigger undesired humoral immune responses in the patients and develop ADA (anti-drug antibody) to the protein drugs. Neutralizing anti-drug antibodies are among the main factors affecting safety and effectiveness of the therapy. If it is impossible to apply cell-based tests to determine neutralizing antibodies, competitive ligand binding assay may be used as an alternative. Pembrolizumab (Pembro) is a broad-spectrum antitumor drug, being a humanized IgG4 kappa antibody to the programmed cell death receptor-1 (PD-1) that blocks interaction of this receptor with its ligands PD-L1 and PD-L2. Due to some technical issues, cell culture test is not feasible for Pembro, due to high risk of obtaining unreliable results. The aim of our study was to develop and validate a method for detection of neutralizing antibodies to Pembro in human serum based on inhibition of pembrolizumab binding to its PD-1 target. The experimental drug pembrolizumab RPH-075 (R-Pharm) was used in the study. Anti-Pembrolizumab antibodies KRIBIOLISATM Anti-Pembrolizumab (KEYTRUDA®) ELISA, India) were used as a positive control sample for neutralizing antibodies. Determination of antibodies was carried out by ELISA technique using acid dissociation of the immune complex and the Affinity capture elution (ACE) technique. The ELISA method was validated by the following characteristics: selectivity, sensitivity, specificity, “hook” effect, drug tolerance, precision. Due to the use of sample pretreatment approaches (ACE technique) for analysis of neutralizing antibodies, a sensitivity level of 100 ng/mL was achieved in the presence of pembrolizumab at 40 μg/mL. In this paper, a method was substantiated by calculating the cutoff point, sensitivity, and selectivity based on ROC analysis and floating exclusion limit (PSCP) through the average values of optical density NC and LPC in each individual analytical cycle. The developed method for determining neutralizing antibodies to pembrolizumab may be used to assess the undesirable immunogenicity of pembrolizumab at the stage of clinical trials.
- Open Access
- 1 October 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (4) , 347-359
Interim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)
AIM. To measure the trough and maximum plasma concentrations of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients on standard and reduced doses of the drugs, to evaluate the impact of TKI plasma concentration on the loss of major/deep molecular response (MR) after dose reduction and the impact of TKI plasma concentration on drug toxicity changes. MATERIALS & METHODS. The trial enrolled 46 imatinib and 16 nilotinib recipients. The trough (Сtrough) and maximum (Cmax) TKI plasma concentrations were measured. On imatinib/nilotinib therapy, Ctrough was analyzed in 104/22 and Cmax was analyzed in 63/15 plasma samples, respectively. RESULTS. The mean plasma imatinib Ctrough values on daily 400 mg, 300 mg, and 200 mg of the drug were 1092 ± 346 ng/mL, 809.5 ± 313.0 ng/mL, and 570.9 ± 280.0 ng/mL, respectively. The mean plasma imatinib Cmax on daily 300 mg and 200 mg were 1944 ± 577 ng/mL and 1233.4 ± 44.0 ng/mL, respectively. In the group of patients without deep MR-loss, on daily 300 mg and 200 mg imatinib, the mean plasma Ctrough values were 773.5 ± 303.0 ng/mL and 586.3 ± 308.0 ng/mL, and the mean Cmax values were 1866.5 ± 532.0 ng/mL and 1283.7 ± 481.0 ng/mL, respectively. In the group of patients with deep MR-loss, on daily 300 mg and 200 mg imatinib, the mean plasma Ctrough values were 774.8 ± 553.0 ng/mL and 490.6 ± 175.0 ng/mL, and the mean Cmax values were 2246 ± 1171 ng/mL and 1124.7 ± 281.0 ng/mL, respectively (p > 0.05). The mean plasma imatinib Ctrough values on daily 400 mg, 300 mg, and 200 mg of the drug in the group of patients with drug toxicity were 1120.6 ± 303.0 ng/mL, whereas in the group without adverse effects these values were 998.4 ± 402.0 ng/mL (p = 0.09). The mean nilotinib Ctrough values on daily 600 mg, 400 mg, and 200 mg were 651.4 ± 397.0 ng/mL, 468.7 ± 220.0 ng/mL, and 376.7 ± 151.0 ng/mL, respectively. The mean nilotinib Cmax values on daily 400 mg and 200 mg were 655.3 ± 189.0 ng/mL and 628 ± 293 ng/mL, respectively. CONCLUSION. This clinical trial yielded differences in plasma imatinib Ctrough and Cmax values in CML patients treated with standard and reduced doses of the drug, which turned out to be significant (p < 0.05). No significant differences in plasma nilotinib Ctrough and Cmax were identified. This trial revealed no significant differences in plasma imatinib Ctrough and Cmax on daily 400 mg and 300 mg of the drug in the groups of patients with and without adverse events. However, while dividing plasma imatinib Ctrough values during the period of 400 mg per day administration into 4 quartiles (Q1 and Q4 included patients with the lowest and the highest Ctrough values, respectively), the proportion of patients with drug toxicity appeared to be the highest in Q4 and accounted for 90 %.
- 1 October 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (4) , 347-359
Open AccessInterim Results of the Russian Prospective Multi-Center Clinical Trial READIT-2020 (Reduction of Tyrosine Kinase Inhibitor Doses in CML Patients, Plasma Imatinib/Nilotinib Concentrations, Sustaining Molecular Response, and Drug Toxicity)
AIM. To measure the trough and maximum plasma concentrations of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients on standard and reduced doses of the drugs, to evaluate the impact of TKI plasma concentration on the loss of major/deep molecular response (MR) after dose reduction and the impact of TKI plasma concentration on drug toxicity changes. MATERIALS & METHODS. The trial enrolled 46 imatinib and 16 nilotinib recipients. The trough (Сtrough) and maximum (Cmax) TKI plasma concentrations were measured. On imatinib/nilotinib therapy, Ctrough was analyzed in 104/22 and Cmax was analyzed in 63/15 plasma samples, respectively. RESULTS. The mean plasma imatinib Ctrough values on daily 400 mg, 300 mg, and 200 mg of the drug were 1092 ± 346 ng/mL, 809.5 ± 313.0 ng/mL, and 570.9 ± 280.0 ng/mL, respectively. The mean plasma imatinib Cmax on daily 300 mg and 200 mg were 1944 ± 577 ng/mL and 1233.4 ± 44.0 ng/mL, respectively. In the group of patients without deep MR-loss, on daily 300 mg and 200 mg imatinib, the mean plasma Ctrough values were 773.5 ± 303.0 ng/mL and 586.3 ± 308.0 ng/mL, and the mean Cmax values were 1866.5 ± 532.0 ng/mL and 1283.7 ± 481.0 ng/mL, respectively. In the group of patients with deep MR-loss, on daily 300 mg and 200 mg imatinib, the mean plasma Ctrough values were 774.8 ± 553.0 ng/mL and 490.6 ± 175.0 ng/mL, and the mean Cmax values were 2246 ± 1171 ng/mL and 1124.7 ± 281.0 ng/mL, respectively (p > 0.05). The mean plasma imatinib Ctrough values on daily 400 mg, 300 mg, and 200 mg of the drug in the group of patients with drug toxicity were 1120.6 ± 303.0 ng/mL, whereas in the group without adverse effects these values were 998.4 ± 402.0 ng/mL (p = 0.09). The mean nilotinib Ctrough values on daily 600 mg, 400 mg, and 200 mg were 651.4 ± 397.0 ng/mL, 468.7 ± 220.0 ng/mL, and 376.7 ± 151.0 ng/mL, respectively. The mean nilotinib Cmax values on daily 400 mg and 200 mg were 655.3 ± 189.0 ng/mL and 628 ± 293 ng/mL, respectively. CONCLUSION. This clinical trial yielded differences in plasma imatinib Ctrough and Cmax values in CML patients treated with standard and reduced doses of the drug, which turned out to be significant (p < 0.05). No significant differences in plasma nilotinib Ctrough and Cmax were identified. This trial revealed no significant differences in plasma imatinib Ctrough and Cmax on daily 400 mg and 300 mg of the drug in the groups of patients with and without adverse events. However, while dividing plasma imatinib Ctrough values during the period of 400 mg per day administration into 4 quartiles (Q1 and Q4 included patients with the lowest and the highest Ctrough values, respectively), the proportion of patients with drug toxicity appeared to be the highest in Q4 and accounted for 90 %.
- Open Access
- 22 January 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 70-82
In-vitro dissolution profiles comparison for various drugs with active ingredient Febuxostat commercially available on the Russian market
Introduction. Gout treatment drugs are widely represented on the pharmaceutical market of the Russian Federation, including those with INN febuxostat. These drugs differ in excipients composition, in the dosage form (tablets and capsules) and production technology. The Dissolution Kinetics Test was chosen to assess the rate and extent of active ingredient release for drugs with INN febuxostat for different manufacturers as in vitro test dissolution allows to suggest the release from the dosage form in vivo. The rate and percent of active substance release are factors that have a direct impact on the bioavailability of drugs. Drug release was studied in a phosphate buffer solution pH 6.8, sampling was carried out at time points 0 min, 5 min, 10 min, 15 min, 20 min, 30 and 45 min. The analysis of the obtained solutions was carried out using the UV spectrophotometry method at a wavelength of 317 nm. The comparison of dissolution profiles was carried out in accordance with the requirements of Decision of the Council of the Eurasian Economic Commission dated November 3, 2016 N 85 "On approval of the Rules for conducting bioequivalence studies of medicinal products within the framework of the Eurasian Economic Union". The purpose of the study. The purpose of this study was to compare the kinetics of the release of the active substance febuxostat from drugs registered in the territory of the Russian Federation in the form of tablets and capsules. Materials and methods. Drug release studies were performed using the Sotax dissolution tester AT Xtend, Switzerland. Each drug was analyzed in 12 repetitions in a pH 6.8 phosphate buffer dissolution medium, on a "Paddle apparatus", special sinkers were used for capsule dosage forms. The selected samples were analyzed on a Shimadzu UV 1800 UV spectrophotometer, Japan, at a wavelength of 317 nm. Results. Dissolution profile studies for three drugs with the active substance febuxostat were conducted in a phosphate buffer solution pH 6,8. For the studied drugs, the release of febuxostat was observed to be more than 85 % at 15 minutes. The release profiles can be recognized as equivalent without further mathematical processing. Conclusion. Based on the results of dissolution profile studies, no differences were found in dissolution profiles of febuxostat from drugs with different dosage forms (tablets and capsules).
- 22 January 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 70-82
Open AccessIn-vitro dissolution profiles comparison for various drugs with active ingredient Febuxostat commercially available on the Russian market
Introduction. Gout treatment drugs are widely represented on the pharmaceutical market of the Russian Federation, including those with INN febuxostat. These drugs differ in excipients composition, in the dosage form (tablets and capsules) and production technology. The Dissolution Kinetics Test was chosen to assess the rate and extent of active ingredient release for drugs with INN febuxostat for different manufacturers as in vitro test dissolution allows to suggest the release from the dosage form in vivo. The rate and percent of active substance release are factors that have a direct impact on the bioavailability of drugs. Drug release was studied in a phosphate buffer solution pH 6.8, sampling was carried out at time points 0 min, 5 min, 10 min, 15 min, 20 min, 30 and 45 min. The analysis of the obtained solutions was carried out using the UV spectrophotometry method at a wavelength of 317 nm. The comparison of dissolution profiles was carried out in accordance with the requirements of Decision of the Council of the Eurasian Economic Commission dated November 3, 2016 N 85 "On approval of the Rules for conducting bioequivalence studies of medicinal products within the framework of the Eurasian Economic Union". The purpose of the study. The purpose of this study was to compare the kinetics of the release of the active substance febuxostat from drugs registered in the territory of the Russian Federation in the form of tablets and capsules. Materials and methods. Drug release studies were performed using the Sotax dissolution tester AT Xtend, Switzerland. Each drug was analyzed in 12 repetitions in a pH 6.8 phosphate buffer dissolution medium, on a "Paddle apparatus", special sinkers were used for capsule dosage forms. The selected samples were analyzed on a Shimadzu UV 1800 UV spectrophotometer, Japan, at a wavelength of 317 nm. Results. Dissolution profile studies for three drugs with the active substance febuxostat were conducted in a phosphate buffer solution pH 6,8. For the studied drugs, the release of febuxostat was observed to be more than 85 % at 15 minutes. The release profiles can be recognized as equivalent without further mathematical processing. Conclusion. Based on the results of dissolution profile studies, no differences were found in dissolution profiles of febuxostat from drugs with different dosage forms (tablets and capsules).
- Open Access
- 28 February 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (1) , 142-153
Pharmacokinetic and Bioequivalence Study of the Two-component Drug Product "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia): Resuts and Experience with the Use of Enzymatic Hydrolysis in the Analysis of Samples
Introduction. As a part of the registration of the drug product a bioequivalence study of the fixed-dose combination "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia) compared with coadministered Ezetrol® (ezetimibe) and Crestor® (rosuvastatin) was conducted with 76 healthy volunteers. Enzymatic hydrolysis was used to evaluate the pharmacokinetics of total ezetimibe. This was the reason for the inclusion of the additional monitored parameters in the validation and analysis.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed-dose combination "Ezetimibe + rosuvastatin" (ezetimibe + rosuvastatin,tablets, 10 + 40 mg, JSC "Sanofi-aventis group", Russia) compared with coadministrated monocomponent drugs ezetimibe and rosuvastatin in fasting healthy volunteers after a single administration using the described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide during the analysis of samples.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover two-period clinical trial was conducted. During the study, blood plasma samples were taken from volunteers, the concentrations of ezetimibe (unconjugated) and total ezetimibe (ezetimibe + ezetimibe-glucuronide) and rosuvastatin in plasma samples were determined by validated HPLC-MS/MS methods. Based on the received data pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of ezetimibe (free) and rosuvastatin. Pharmacokinetic parameters of total ezetimibe were considered as secondary and were not required for the conclusion on bioequivalence. While HPLC-MS/MS analysis of incurred samples, additional control parameters for the enzymatic hydrolysis of ezetimibe-glucuronide made it possible to legitimately reject the results of inaccurate analytical batches.Conclusion. Thus, according to the criteria used in the study, the drugs are proved to be bioequivalent. The described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide have been shown to be effective.
- 28 February 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (1) , 142-153
Open AccessPharmacokinetic and Bioequivalence Study of the Two-component Drug Product "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia): Resuts and Experience with the Use of Enzymatic Hydrolysis in the Analysis of Samples
Introduction. As a part of the registration of the drug product a bioequivalence study of the fixed-dose combination "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia) compared with coadministered Ezetrol® (ezetimibe) and Crestor® (rosuvastatin) was conducted with 76 healthy volunteers. Enzymatic hydrolysis was used to evaluate the pharmacokinetics of total ezetimibe. This was the reason for the inclusion of the additional monitored parameters in the validation and analysis.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed-dose combination "Ezetimibe + rosuvastatin" (ezetimibe + rosuvastatin,tablets, 10 + 40 mg, JSC "Sanofi-aventis group", Russia) compared with coadministrated monocomponent drugs ezetimibe and rosuvastatin in fasting healthy volunteers after a single administration using the described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide during the analysis of samples.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover two-period clinical trial was conducted. During the study, blood plasma samples were taken from volunteers, the concentrations of ezetimibe (unconjugated) and total ezetimibe (ezetimibe + ezetimibe-glucuronide) and rosuvastatin in plasma samples were determined by validated HPLC-MS/MS methods. Based on the received data pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of ezetimibe (free) and rosuvastatin. Pharmacokinetic parameters of total ezetimibe were considered as secondary and were not required for the conclusion on bioequivalence. While HPLC-MS/MS analysis of incurred samples, additional control parameters for the enzymatic hydrolysis of ezetimibe-glucuronide made it possible to legitimately reject the results of inaccurate analytical batches.Conclusion. Thus, according to the criteria used in the study, the drugs are proved to be bioequivalent. The described additional parameters for controlling the enzymatic hydrolysis of ezetimibe-glucuronide have been shown to be effective.
- Open Access
- 27 February 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (1) , 131-141
Dissolution Profile Study and Uniformity of Dosage Units Test for Various Manufacturers of "Captopril" Drugs from the Russian Market
Introduction. As part of a comparative assessment of drugs quality available on the Russian market a dissolution profile studies and uniformity of dosage units test was conducted for various manufacturers of "Captopril" drugs. Drug release studies in three dissolution media (0.1 M hydrochloric acid, acetate buffer pH 4.5, phosphate buffer pH 6.8) with sampling at 0, 5, 10, 15, 20, 30 min and analysis using UV/Vis spectrophotometer at 212 nm were conducted. Dissolution kinetics was compared based on calculation of the similarity factor f2 and the values of relative standard deviations. Uniformity of dosage units test of scored tablets were evaluated based on HPLC-UV analysis and AV factor calculation.Aim. The purpose of this study was a comparative evaluation of "Captopril" drugs from various manufacturers on the Russian market based on dissolution profile studies and uniformity of dosage units test of scored tablets in order to assess the quality of the tablets.Materials and methods. To prove the dissolution profile studies DT 827/1000 tester (ERWEKA GmbH, Germany) was applied. Each drug in three dissolution media in 12 replicates for each dissolution medium was analyzed. The selected samples were analyzed on a UV 1800 UV spectrophotometer (Shimadzu, Japan) at a of 212 nm. In uniformity of dosage units test of scored tablets each tablet was divided according to the applied mark. Sample preparation was carried out in accordance with a validated method and samples were analyzed by HPLC-UV using Agilent 1260 (Agilent Technologies, США).Results and discussion. Based on the results of dissolution profile studies and calculations of the similarity factors and values of the relative standard deviation it can be concluded that the dissolution kinetics for drug no. 4, drug no. 5, drug no. 6 are not equivalent in comparison with the reference drug. During the uniformity of dosage units test of scored tablets, no deviations were found in accordance with the requirements of the RF Pharmacopoeia OFS.1.4.2.0008.18 "Uniformity of dosing" and the EAEU Pharmacopoeia OFS.2.1.9.14 "Uniformity of Dosed Units".Conclusion. The conducted dissolution profile studies and uniformity of dosage for scored tablets of Captopril drugs show the example of possibility to identify potential problems with drugs quality presented on the Russian market and as a result improve and maintain quality assurance of drugs for the national healthcare system.
- 27 February 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (1) , 131-141
Open AccessDissolution Profile Study and Uniformity of Dosage Units Test for Various Manufacturers of "Captopril" Drugs from the Russian Market
Introduction. As part of a comparative assessment of drugs quality available on the Russian market a dissolution profile studies and uniformity of dosage units test was conducted for various manufacturers of "Captopril" drugs. Drug release studies in three dissolution media (0.1 M hydrochloric acid, acetate buffer pH 4.5, phosphate buffer pH 6.8) with sampling at 0, 5, 10, 15, 20, 30 min and analysis using UV/Vis spectrophotometer at 212 nm were conducted. Dissolution kinetics was compared based on calculation of the similarity factor f2 and the values of relative standard deviations. Uniformity of dosage units test of scored tablets were evaluated based on HPLC-UV analysis and AV factor calculation.Aim. The purpose of this study was a comparative evaluation of "Captopril" drugs from various manufacturers on the Russian market based on dissolution profile studies and uniformity of dosage units test of scored tablets in order to assess the quality of the tablets.Materials and methods. To prove the dissolution profile studies DT 827/1000 tester (ERWEKA GmbH, Germany) was applied. Each drug in three dissolution media in 12 replicates for each dissolution medium was analyzed. The selected samples were analyzed on a UV 1800 UV spectrophotometer (Shimadzu, Japan) at a of 212 nm. In uniformity of dosage units test of scored tablets each tablet was divided according to the applied mark. Sample preparation was carried out in accordance with a validated method and samples were analyzed by HPLC-UV using Agilent 1260 (Agilent Technologies, США).Results and discussion. Based on the results of dissolution profile studies and calculations of the similarity factors and values of the relative standard deviation it can be concluded that the dissolution kinetics for drug no. 4, drug no. 5, drug no. 6 are not equivalent in comparison with the reference drug. During the uniformity of dosage units test of scored tablets, no deviations were found in accordance with the requirements of the RF Pharmacopoeia OFS.1.4.2.0008.18 "Uniformity of dosing" and the EAEU Pharmacopoeia OFS.2.1.9.14 "Uniformity of Dosed Units".Conclusion. The conducted dissolution profile studies and uniformity of dosage for scored tablets of Captopril drugs show the example of possibility to identify potential problems with drugs quality presented on the Russian market and as a result improve and maintain quality assurance of drugs for the national healthcare system.
- Open Access
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 69-77
Pharmacokinetic and bioequivalence study of Telzap® Plus fixed-dose combination compared with MikardisPlus® in healthy volunteers after single administration
Introduction. A fixed dose combination of telmisartan and hydrochlorothiazide is indicated for treatment of in the treatment of arterial hypertension. The combination of these substances causes an additive effect that helps to reduce blood pressure. A bioequivalence study of Telzap® Plus compared with MikardisPlus® was conducted with 63 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed dose combination drug product Telzap® Plus (tablets 80 mg + 12,5 mg, Zentiva KS company, Czech Republic) compared with drug products MikardisPlus® (telmisartan+hydrochlorothiazide, tablets 80 mg + 12,5 mg, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover fourperiod replicate single-center clinical trial was conducted. The concentrations of hydrochlorothiazide and telmisartan in plasma samples were determined with a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of hydrochlorothiazide and telmisartan. All 90 % confidence intervals for the estimated pharmacokinetic parameters of hydrochlorothiazide were in the range of 80–125 %, 90 % confidence intervals for telmisartan were within the bioequivalence range of 80–125 % for AUC0-72, and 79,30–126,11 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 69-77
Open AccessPharmacokinetic and bioequivalence study of Telzap® Plus fixed-dose combination compared with MikardisPlus® in healthy volunteers after single administration
Introduction. A fixed dose combination of telmisartan and hydrochlorothiazide is indicated for treatment of in the treatment of arterial hypertension. The combination of these substances causes an additive effect that helps to reduce blood pressure. A bioequivalence study of Telzap® Plus compared with MikardisPlus® was conducted with 63 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of the fixed dose combination drug product Telzap® Plus (tablets 80 mg + 12,5 mg, Zentiva KS company, Czech Republic) compared with drug products MikardisPlus® (telmisartan+hydrochlorothiazide, tablets 80 mg + 12,5 mg, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover fourperiod replicate single-center clinical trial was conducted. The concentrations of hydrochlorothiazide and telmisartan in plasma samples were determined with a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of hydrochlorothiazide and telmisartan. All 90 % confidence intervals for the estimated pharmacokinetic parameters of hydrochlorothiazide were in the range of 80–125 %, 90 % confidence intervals for telmisartan were within the bioequivalence range of 80–125 % for AUC0-72, and 79,30–126,11 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- Open Access
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 62-68
Pharmacokinetic and bioequivalence study of Telzap® in comparison with Mikardis® in healthy subjects after single administrationl
Introduction. Telmisartan is widely used in clinical practice during hypertension treatment. It is a specific angiotensin II receptor antagonist (type AT1), effective at oral intake, A bioequivalence study of Telzap® and Mikardis® was conducted with 60 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of Mikardis® (telmisartan, tablets 80 mg, Boehringer Ingelheim International GmbH, Germany) and Telzap® (telmisartan, tablets 80 mg, Zentiva KS company, Czech Republic) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period replicate single-center clinical trial was conducted. The concentrations of telmisartan in plasma samples were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of test and reference drug. All 90 % confidence intervals of were within the bioequivalence range of 80–125 % for AUC0-72 and 73,07–136,85 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- 19 January 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 62-68
Open AccessPharmacokinetic and bioequivalence study of Telzap® in comparison with Mikardis® in healthy subjects after single administrationl
Introduction. Telmisartan is widely used in clinical practice during hypertension treatment. It is a specific angiotensin II receptor antagonist (type AT1), effective at oral intake, A bioequivalence study of Telzap® and Mikardis® was conducted with 60 volunteers.Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of Mikardis® (telmisartan, tablets 80 mg, Boehringer Ingelheim International GmbH, Germany) and Telzap® (telmisartan, tablets 80 mg, Zentiva KS company, Czech Republic) in healthy volunteers after a single administration under fasting.Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period replicate single-center clinical trial was conducted. The concentrations of telmisartan in plasma samples were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals for the pharmacokinetic parameters Cmax and AUC0-72 were calculated.Results and discussion. It can be concluded that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of test and reference drug. All 90 % confidence intervals of were within the bioequivalence range of 80–125 % for AUC0-72 and 73,07–136,85 % for Cmax.Conclusion. Thus, according to the criteria used in the study, the formulations are proved to be bioequivalent.
- Open Access
- 1 May 2022
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 61-74
Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier to take which helps to improve patient adherence to therapy. A bioequivalence study of the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi with coadministered Lozap® AM (Losartan+Amlodipine) and Crestor® (Rosuvastatin) was conducted. Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of two strengths of fixed-dose combination: 1) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 50 mg + 5 mg + 10 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 50 mg + 5 mg,) and Crestor® (rosuvastatin, tablets, 10 mg) in fasting healthy volunteers after a single administration; 2) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 100 mg + 5 mg + 20 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 100 mg + 5 mg) and Crestor® (rosuvastatin, tablets, 20 mg) in fasting healthy volunteers 18–45 years old after a single dose. Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period clinical trial was conducted for each strengths of fixed-dose combination. The concentrations of losartan, amlodipine and rosuvastatin in blood plasma samples obtained from volunteers were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Сmax, AUC0-72 (for amlodipine) and AUC0-t (for losartan and rosuvastatin) were calculated. Results and discussion. Based on the results of statistical and pharmacokinetic analysis, it was shown that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of losartan, amlodipine and rosuvastatin. 90 % CI were in the acceptable range for Сmax (of amlodipine), AUC0-72 (of amlodipine) and AUC0-t (of losartan and rosuvastatin). 90 % CI for Сmax of losartan and rosuvastatin were in the acceptable extended calculated range according to the protocol. Conclusion. Thus, according to the criteria used in the studies, the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi are proved to be bioequivalent in comparison with coadministered Lozap® AM and Crestor®.
- 1 May 2022
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 61-74
Open AccessBioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier to take which helps to improve patient adherence to therapy. A bioequivalence study of the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi with coadministered Lozap® AM (Losartan+Amlodipine) and Crestor® (Rosuvastatin) was conducted. Aim. The purpose of the bioequivalence trial was a comparative study of the pharmacokinetics and evidence of the bioequivalence of two strengths of fixed-dose combination: 1) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 50 mg + 5 mg + 10 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 50 mg + 5 mg,) and Crestor® (rosuvastatin, tablets, 10 mg) in fasting healthy volunteers after a single administration; 2) Losartan + amlodipine + rosuvastatin Sanofi (tablets, 100 mg + 5 mg + 20 mg) in comparison with coadministrated drugs Lozap® AM (losartan + amlodipine, tablets, 100 mg + 5 mg) and Crestor® (rosuvastatin, tablets, 20 mg) in fasting healthy volunteers 18–45 years old after a single dose. Materials and methods. To prove bioequivalence, an open label, comparative, randomized, crossover four-period clinical trial was conducted for each strengths of fixed-dose combination. The concentrations of losartan, amlodipine and rosuvastatin in blood plasma samples obtained from volunteers were determined by a validated HPLC-MS/MS method. A pharmacokinetic and statistical analysis was performed and confidence intervals (CI) for the pharmacokinetic parameters Сmax, AUC0-72 (for amlodipine) and AUC0-t (for losartan and rosuvastatin) were calculated. Results and discussion. Based on the results of statistical and pharmacokinetic analysis, it was shown that the studied formulations are bioequivalent in terms of pharmacokinetic parameters of losartan, amlodipine and rosuvastatin. 90 % CI were in the acceptable range for Сmax (of amlodipine), AUC0-72 (of amlodipine) and AUC0-t (of losartan and rosuvastatin). 90 % CI for Сmax of losartan and rosuvastatin were in the acceptable extended calculated range according to the protocol. Conclusion. Thus, according to the criteria used in the studies, the three-component fixed-dose combinations Losartan + amlodipine + rosuvastatin Sanofi are proved to be bioequivalent in comparison with coadministered Lozap® AM and Crestor®.
- 6 December 2017
- Published by Springer Nature
- p. 199-227
Russia, Belarus & Kazakhstan